Latest News and Press Releases
Want to stay updated on the latest news?
-
Delhi, April 02, 2025 (GLOBE NEWSWIRE) -- Global Natural Killer (NK) Cell Therapy Clinical Trials, Proprietary Technologies, Collaborations and Market Opportunity Insight 2025 Report Highlights...
-
New York, USA, Feb. 28, 2025 (GLOBE NEWSWIRE) -- NK Cell Therapy Market on Track for Exponential Growth Amid Rising Pipeline Developments | DelveInsight The NK cell therapy market is experiencing...
-
The world’s first zero-off-target base-edited NK cell product has received IND approvals from both the U.S. FDA and China’s NMPA.
-
Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering
-
NKGen Biotech, Inc. (“NKGen”), a clinical stage Natural Killer (NK) cell therapy company, has entered into a merger agreement with Graf Acquisition Corp. IV NKGen Biotech, Inc.’s non-genetically...
-
Delhi, March 20, 2023 (GLOBE NEWSWIRE) -- Global Natural Killer (NK) Cell Therapeutics Market Trends, Companies & Clinical Trials Insight 2023 Report Highlights: Global Natural Killer (NK)...
-
SANTA ANA, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body’s immune system through the development of natural killer (NK) cell...
-
SANTA ANA, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body’s immune system through the development of natural killer cell therapies,...
-
SANTA ANA, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc., a biotechnology company harnessing the power of the body’s immune system through the development of natural killer (NK) cell...
-
SANTA ANA, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc., a biotechnology company harnessing the power of the body’s immune system through the development of natural killer (NK) cell...